ALMS: Envudicitinib shows efficacy in lupus and psoriasis subgroups
ALMS said its phase IIb lupus trial failed overall, citing a high proportion of interferon signature negative patients, but showed strong efficacy in interferon signature positive subgroups. Regulatory discussions are planned, and a psoriasis NDA submission is planned.
Envudicitinib’s phase IIb lupus trial failed to deliver an overall result because a high proportion of patients were interferon signature negative, but the drug showed strong efficacy in signature positive subgroups. Future development will focus on those patients, with regulatory discussions planned, and a psoriasis NDA submission ex…